PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 36: Articles 17501-18000 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. The use of cost-benefit analysis to encourage private sector investment in family planning.
  2. Use of maternal-child health services and contraception in Guatemala and Panama.
  3. Use of nutrition surveys for family planning programme evaluation--the case of the Arab Republic of Egypt Nutrition Status.
  4. Use of oral contraceptives and risk of invasive cervical cancer in previously screened women.
  5. The use of peptides for contraception. [Ispolzovanie peptidov s tseliu kontratseptsii.]
  6. Use-effectiveness of oral pill, loop, Cu-T and Multiload in Taiwan area (based on 1985 follow-up survey of contraceptive acceptors in Taiwan area)
  7. User's attitudes about Norplant contraceptive subdermal implants and changes that occur with use of the method. Answers to pre-coded questions, Dominican Republic.
  8. Using public transit advertising to increase public awareness of family planning services.
  9. Using statistical risk information to assess oral contraceptive safety.
  10. Utero-ovarian actinomycosis and intrauterine contraceptive device. [Actinomycose utero-ovarienne et dispositif contraceptif intra-uterin.]
  11. Vaginal cytology in women using oral contraceptives.
  12. Vascular thrombosis and oral contraceptives. [Thromboses vasculaires et contraceptifs oraux.]
  13. Voluntary Choice and Surgical Contraception: report of a Leader's Symposium.
  14. Voluntary Surgical Contraception (VSC), experience in the private sector.
  15. Voluntary surgical contraception in the national family planning program in Haiti. [La contraception chirurgicale volontaire dans le programme national de planification familiale en Haiti.]
  16. Voluntary Surgical Contraception Quality Assurance and Management in Nigeria. Report of a service providers / managers conference - Jos, Nigeria, October 19 - 22, 1987.
  17. Wallcharts on contraceptive methods. Information packet] [Graficas murales sobre metodos anticonceptivos.]
  18. The way ahead for family planning in Bangladesh.
  19. What Abidjan residents think about family planning: report of group interviews taken in Abidjan. [Ce que les Abidjanais pensent du planning familial (compte-rendu d'interviews de groupes realisees a Abidjan)]
  20. What do the surveys say about the necessity of communication in family planning? Preliminary conclusions. [Que nos dicen las encuestas acerca de las necesidades de comunicacion en planificacion familiar? Conclusiones preliminares.]
  21. What is a family planning program? [Que es un programa de planificacion familiar?]
  22. Which birth control pill should be prescribed--today?
  23. Whither family planning [editorial]
  24. Why no progress in male contraception?
  25. Woman to woman: community-based distribution of family planning services in sub-Saharan Africa.
  26. Women in a maize storage co-operative in Nigeria. Family planning, credit and technological change.
  27. Women to women: facilitating decision-making about contraception.
  28. Women's health and family planning. [Saude da mulher e planejamento familiar.]
  29. Women's status and family planning in Haiti.
  30. Women's status, breastfeeding patterns and contraceptive use in rural Kenya.
  31. Workers' Health and Family Planning Project, Turkey-05 Modification No. 10: project description and budget.
  32. Workshop on Family Health/Family Planning Broadcasting, August 31 to September 4, 1987. Communique.
  33. World access to birth control. [Wallchart]
  34. World contraceptive use, 1987.
  35. World contraceptive use. [Wallchart]
  36. Young adults' contraceptive practices: an investigation of influences.
  37. Young girls and contraception. A survey conducted in the MFPF family planning center, Strasbourg, in 1985. [Les jeunes filles et la contraception. Enquete realisee dans le centre de planification du MFPF a Strasbourg en 1985.]
  38. Young people of Tavira do not practice contraception. [Jovens de Tavira desconhecem contracepcao.]
  39. Zimbabwe Contraceptive Knowledge, Attitudes and Practices Baseline Survey, October 1987.
  40. Zona pellucida: current status as a candidate antigen for contraceptive vaccine development.
  41. Zonal Workshop on Family Planning Awareness Campaign for Local Government Women Councillors.
  42. The `unreached' in family planning: a case study of the Republic of Korea.
  43. Do oral contraceptives prevent rheumatoid arthritis? In reply [letter]
  44. A multi-compartment vaginal ring system for independently adjustable release of contraceptive steroids.
  45. A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100mg or 150mg: I. Contraceptive efficacy and side effects.
  46. Endocervical neoplasia in long-term users of oral contraceptives: clinical and pathologic observations.
  47. Evaluation of a new triphasic oral contraceptive in private practice.
  48. The ability of women to recall their oral contraceptive histories.
  49. Arteriosclerosis risk in women and the role of oral contraceptive progestins.
  50. Arteriosclerosis risk: the roles of oral contraceptives and postmenopausal estrogens.
  51. Bacterial flora of the cervix in women using different methods of contraception.
  52. The biochemistry of human endometrium after two regimens of postcoital contraception: a dl-norgestrel/ethinylestradiol combination or danazol.
  53. Carbohydrate metabolism in women who used oral contraceptives containing levonorgestrel or desogestrel: a 6-month prospective study.
  54. A case-control study of breast cancer in relation to the use of steroid contraceptive agents.
  55. Chronic inflammatory bowel disease, cigarette smoking, and use of oral contraceptives: findings in a large cohort study of women of childbearing age.
  56. Clinical experience with Diane-35, the antiandrogenic hormonal contraceptive currently with the lowest dose, in women manifesting slight to moderate androgenization. [Klinische Erfahrungen mit Diane-35, dem zur Zeit niedrigst dosierten antiandrogen wirkenden hormonalen Ovulationshemmer, bei leichten bis mittelstarken Androgenisierungserscheinungen der Frau.]
  57. Clinical experience with multiphasic oral contraceptives.
  58. A comparative study of the metabolic effects of injectable and oral contraceptives.
  59. Contraception and birthspacing.
  60. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.
  61. Contraception in diabetic women.
  62. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
  63. Contraception with the cervical cap: effectiveness, safety, continuity of use, and user satisfaction.
  64. The contraceptive and hormonal requirements of the premenopausal woman: the years from forty to fifty.
  65. The contraceptive efficacy of a Cu-IUD: size of the device and the uterine cavity.
  66. Contraceptive experience and attitudes to motherhood of teenage mothers.
  67. Contraceptive use and the need for family planning in Puerto Rico.
  68. Correlation of vaginal hormonal cytograms with cervical mucus symptoms as observed by women using the ovulation method of natural family planning.
  69. Criteria for selective screening for Chlamydia trachomatis infection in women attending family planning clinics.
  70. The effect of age, weight-related parameters and hormonal contraceptives on andrological assays.
  71. Effect of oral contraceptive on liver function tests of women with schistosomiasis in the Philippines.
  72. Effect of oral contraceptives on plasma and platelet lipid composition: influence of the length duration of time of ingestion.
  73. The effect of the contraceptive pill on blood pressure: a randomized controlled trial of three progestogen-oestrogen combinations in Szeged, Hungary.
  74. The effect of vaginal administration of low-dose oral contraceptive tablets on human ovulation.
  75. Effects of hormonal and nonhormonal contraceptives on lactation and incidence of pregnancy.
  76. Effects on the lipoprotein metabolism of an antiandrogen-estrogen oral contraceptive drug.
  77. Fertility and family planning surveys: future priorities in the light of past experiences.
  78. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
  79. Human seminal antiliquefying agents: a potential approach towards vaginal contraception.
  80. Humoral immune response in women using intrauterine contraceptive device.
  81. Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives.
  82. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens.
  83. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.
  84. An investigation on the influence of steroidal contraceptives on milk lipid and fatty acids in Hungary and Thailand. (WHO Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Oral Contraceptives)
  85. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids.
  86. Laparoscopic tubal sterilization combined with removal of an intrauterine contraceptive device: a report of 49 cases.
  87. Lipid, carbohydrate, and androgen metabolism in women using a triphasic oral contraceptive containing norethindrone for one year.
  88. Literacy, parity, family planning, and maternal mortality in the Third World [letter]
  89. Liver disorders related to the use of oral contraceptives. [Oralis kontraceptiv szerek szedesevel kapcsolatos majelvaltozasok.]
  90. A meta-analysis of research on adolescent contraceptive use.
  91. Metabolic effects of low-dose combined oral contraceptives. [Kis dozisu kombinalt fogamzasgatlo tablettak anyagcserehatasai.]
  92. Monitoring a post-coital contraception service.
  93. On cohort effects in studies on oral contraceptive use and breast cancer [letter]
  94. On the reliability of the vaginal diaphragm as a contraceptive method. [Uber die Zuverlassigkeit des Scheiden-Diaphragma als kontrazeptive Methode.]
  95. Opioid regulation of pituitary gonadotropins and prolactin in women using oral contraceptives.
  96. Oral contraceptive use has no adverse effect on the prognosis of breast cancer.
  97. Oral contraceptive use modifies the manifestations of pelvic inflammatory disease.
  98. Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study.
  99. Oral contraceptives and insulin receptor binding in normal women and those with previous gestational diabetes.
  100. Parity and use-effectiveness with the contraceptive sponge.
  101. Patterns of contraceptive pill taking in an inner city practice.
  102. Patterns of contraceptive use in China.
  103. Patterns of depo-provera use in a large family planning clinic in the United States.
  104. Pharmacodynamic assessment of dihydroxyprogesterone acetophenide plus estradiol enanthate as a monthly injectable contraceptive.
  105. Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest.
  106. Phase II randomized comparative clinical trial of Norplant (R) (six capsules) with Norplant(R)-2 (two covered rods) subdermal implants for long term contraception: report of a 24-month study.
  107. A possible mechanism of action of danazol and an ethinylestradiol/norgestrel combination used as postcoital contraceptive agents.
  108. Post-coital contraception by estrogen/progestagen combination or IUD insertion.
  109. The postcoital IUD as an effective continuing contraceptive method.
  110. Public funding of contraceptive, sterilization and abortion services, 1985.
  111. Quantitative transcervical uterine cultures in asymptomatic women using an intrauterine contraceptive device.
  112. The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive.
  113. Results of a representative survey of family planning behavior in the Federal Republic of Germany. [Ergebnisse einer reprasentativen Umfrage zum Familienplanungsverhalten in der Bundesrepublik Deutschland 1985.]
  114. Return of fertility after discontinuation of oral contraceptives: influence of age and parity.
  115. Return of fertility following discontinuation of an injectable contraceptive--norethisterone oenanthate (NET EN) 200mg dose.
  116. Screening for sexually transmitted diseases by family planning providers: is it adequate and appropriate?
  117. Selection of steroid combinations for oral contraceptives of maximum benefit.
  118. Serum nickel concentration in normal menstrual cycle and after combined contraceptive pill.
  119. A study of women requesting interval contraceptive sterilization who do and do not return for surgery.
  120. Toxic shock syndrome and the vaginal contraceptive sponge.
  121. Toxic shock syndrome, contraceptive methods, and vaginitis.
  122. The United Nations convention on the rights of women: opportunities for family planning providers.
  123. Use of oral contraceptives by women with epilepsy.

     

  124. Men--new focus for family planning programs./L'homme dans les programmes de planning familiale - nouvelles orientations./Os homens - novo enfoque para os programas de planejamento familiar.
  125. Radio--spreading the word on family planning./La radio : difusion mundial de la planificacion familiar./O radio - divulgando o planejamento familiar./La radio: difusion mundial de la planificacion familiar.
  126. Desogestrel-containing oral contraceptives and blood pressure.
  127. Determinants of contraceptive method choice in Peninsular Malaysia, 1961-1975.
  128. Determinants of contraceptive method choice in Thailand.
  129. Determinants of oral contraceptive use in northern Italy.
  130. Determination of the viscosity of vehicles for vaginal contraceptives with sodium carboxymethylcellulose and Veegum HV.
  131. Determining infertile days in the female cycle. Initial test results of technical aids for methods of natural family planning. [Bestimmung der unfructbaren Tage in Zyklus der Frau. Erste Prufergebnisse uber technische Hilfsmittel bei Methoden der naturlichen Familienplanung.]
  132. Develop family planning work based on the reality of minority regions.
  133. Development of a contraceptive vaccine [abstract]
  134. The development of a contraceptive vaccine by purification of antigens from gametes.
  135. The development of national economy and family planning in China.
  136. The development of planned parenthood in the United Kingdom.
  137. Development of scope of work statement for a management case study of the Mexican Social Security Institute Family Planning Program: trip report.
  138. The development of training capacity for the introduction of new contraceptive technology.
  139. Diabetes and contraception - standpoint of the SDA, Swiss Diabetes Association. [Directives de l'ASD concernant diabete et contraception.]
  140. Diarrheal disease control and family planning: the status of women and community participation.
  141. Differences in coagulation and haemostatic parameters in normal women of childbearing age from different ethnic groups and geographical locations. Task Force on Oral Contraceptives--WHO Special Programme of Research, Development and Research Training in Human Reproduction.
  142. Difficulties in female contraception resulting from sexual and emotional problems. [Contraceptions difficiles pour la femme parce que sa vie sexuelle et affective est difficile.]
  143. Difficulties with contraception and voluntary pregnancy termination: a survey carried out at the hopital Saint-Louis. [Contraception difficile et IVG, a propos d'une enquete realisee a l'hopital Saint-Louis.]
  144. Discussion: experimental approaches for male contraception.
  145. Discussion: male reproductive physiology and contraception.
  146. Distribution of family planning services by micro-businesswomen. [Operations Research Project Summary]
  147. The diurnal increase in euglobulin fibrinolytic activity in women using oral contraceptives and in normal women, and the generation of intrinsic fibrinolytic activity.
  148. Do contraceptives prices affect demand?
  149. Do oral contraceptive agents affect nutrient requirements--vitamin B-6?
  150. Do oral contraceptives prevent rheumatoid arthritis? [letter]
  151. Does better contraception improve women's status?
  152. Dr George Morris Memorial Lecture 1986: counter reformation in family planning.
  153. Dr. Haryono Suyono, National Family Planning Coordinating Board, Indonesia.
  154. Drug information. This is how hormonal contraceptives act. [Laegemiddelinformation. Sadan virker de hormonale kontraceptiva.]
  155. Drug interactions with oral contraceptive preparations.
  156. Drug interactions with oral contraceptives.
  157. Drugs with contraceptive actions and periodontal status. Epidemiological survey. [Farmaci ad azione contraccettiva e condizioni parodontali. Indagine epidemiologica.]
  158. A dynamic family planning and health campaign.
  159. Morphological characteristics of incrustates of intrauterine contraceptive devices.
  160. Morphology, incidence and clinical significance of changes in the liver parenchyma following use of oral contraceptives. [Morphologie, Haufigkeit und klinische Bedeutung von Leberparenchymveranderungen nach Anwendung hormonaler Kontrazeptiva.]
  161. Mortality attributable to voluntary surgical contraception in international programs [tables]
  162. Motivational facilities for family planning acceptance in a rural set-up: a micro study.
  163. Motivations for adolescents' first visit to a family planning clinic.
  164. The multilevel approach to family planning program evaluation.
  165. The multilevel dependence of contraceptive use on socioeconomic development and family planning program strength.
  166. A multiple regression analysis of variables associated with the use or non-use of contraceptives by teenaged Bermudian high school students.
  167. Multivariate areal analysis of the efficiency of family planning programme and its impact on fertility in Bangladesh. Country report of Bangladesh.
  168. Multivariate areal analysis of the efficiency of family planning programme and its impact on fertility in Thailand.
  169. National Family Planning Program and fertility decline in Indonesia.
  170. National Family Planning Program. Strategies for extension of coverage. [Programa Nacional de Planificacion Familiar. Estrategias de extension de cobertura.]
  171. Natural family planning and an integral vision of the person.
  172. Natural family planning, guide for practice. 7th edition. [Planificacion familiar natural, gia para su practica. septima edicion.]
  173. Natural family planning: an update.
  174. Natural methods of family planning.
  175. NCIH poster session: JHU / PCS evaluation of Nepali family planning booklets.
  176. Nepal: evaluation of family planning booklets.
  177. Neurology of sex steroids and oral contraceptives.
  178. A new aspect for family planning opened up by "eight visits".
  179. A new contraceptive: Marvelon. [Ny p-pille: Marvelon.]
  180. New delivery systems for hormonal contraception.
  181. New developments in oral, injectable and implantable contraceptives, vaginal rings and intrauterine devices: a review.
  182. New directions in population/family planning communication: a global perspective from Johns Hopkins University/Population Communication Services.
  183. A new era in contraceptive counseling for early adolescents.
  184. The new no-pill, no-risk birth control.
  185. New observations in the sonographic evaluation of intrauterine contraceptive devices.
  186. New oral contraception study: pilot trial report, Royal College of General Practitioners, Manchester Research Unit.
  187. The new policies of natural birth control. [Les nouvelles politiques de regulation naturelle des naissances.]
  188. The new politics of natural family planning.
  189. New potential for family planning: preconceptional health promotion programs.
  190. New progress in research on contraceptive technology.
  191. New steroidal contraceptives, implications for toxicological models.
  192. New Zealand contraception and health study: design and preliminary report.
  193. Elusive Mr. Right: the social and personal context of a young woman's use of contraception.
  194. Embolic stroke in a woman with mitral valve prolapse who used oral contraceptives.
  195. Employee-based family planning programs in the developing world.
  196. Encephalopathy in renovascular hypertension associated with the use of oral contraceptives.
  197. Endocrine control of human spermatogenesis: possible mechanisms for contraception.
  198. Endocrine effects of systemic, steroidal contraceptives.
  199. Epidemiologic assessment of the risks of oral contraception.
  200. An epidemiological study on the relationship between oral contraceptives and benign breast disease. [Etude epidemiologique sur la relation des contraceptifs oraux avec les maladies benignes du sein.]
  201. Epidemiology of oral contraceptives and the risk of breast cancer.
  202. Estrogen and progesterone receptors in human liver--does their analysis improve the understanding of benign liver tumors associated with oral contraceptive use. [Ostrogen-und Progesteron-Rezeptoren der menschlichen Leber: tragt deren Untersuchung zum besseren Verstandnis gutartiger, kontrazeptiva-assoziierter Lebertumoren bei?]
  203. Evaluating family planning print materials cross-nationally: the Mexico-Nigeria experience.
  204. Evaluating the effects of optimally distributed public programs: child health and family planning interventions.
  205. Evaluation of AID's Family Planning International Assistance (FPIA) cooperative agreement.
  206. Evaluation of contraceptive history data in the Republic of Korea.
  207. Evaluation of family planning services delivered at home, Turkey, [Bursa Medical School, Department of Community Medicine]. Operations research project summary.
  208. Evaluation of the non-governmental organizations component of the Family Planning Services Project: USAID/Bangladesh.
  209. Evaluation of the training programe of health and family planning field workers.
  210. Evaluation of the USAID grant to the International Center for Diarrheal Disease Research, Bangladesh: Maternal and Child Health/Family Planning Extension Project.
  211. Evaluation report on family planning programme.
  212. An examination of the concept "risk taking" and its application to the contraceptive behavior of youth.
  213. Examination of the potential interaction between ketoconazole (Nizoral) and oral contraceptives with special regard to products of low hormone content (Rigevidon, Anteovin)
  214. Experience with a hospital-based natural family planning service.
  215. Experience with hormonal contraceptives.
  216. Experiences with family planning in Suriname. [Ervaringen met gezinsplanning in Suriname.]
  217. Experimental studies in the development of male contraceptives.
  218. Extended use of a copper intrauterine device beyond theoretical effectiveness. A ten year study on the Multiload Cu-250 in a gynecologic private practice in Indonesia with specific reference to its use in the national family planning and population program.
  219. The extent of communication regarding family planning between black women in Witbank. [Kommunikasie met betrekking tot gesinsbeplanning onder Swart vroue in Witbank.]
  220. Factors affecting acceptance and non-acceptance of family planning: a study in low income population in Delhi.
  221. Factors affecting achievements in family planning in Bangladesh: a discriminant analysis.
  222. Factors affecting the use and non-use of contraception in urban areas Indonesia.
  223. Family and peer influence on obtaining a method of contraception.
  224. Family communication and contraceptive use among sexually active adolescents.
  225. 'Strictly confidential': birth-control advertising in a 19th-century city.
  226. The 12th Asian Parasite Control/Family Planning Conference proceedings: multi-dimensional development of the integrated project and its future direction.
  227. Abstracts, Fifth International Conference on Voluntary Surgical Contraception.
  228. The acceptability of the contraceptive vaginal ring.
  229. Acceptance of contraceptive practice by grandmultiparae in Benin City, Nigeria.
  230. Actinomyces in cervical smears of women using intrauterine contraceptive devices.
  231. Action area 6: male participation in family planning. IPPF plan 1988-90.
  232. Action of hormonal contraceptives on the coagulation system and some of its inhibitors.
  233. Acute myocardial infarction in a young woman taking oral contraceptives: a case report.
  234. Acute salpingitis and contraceptive use. [Akutt salpingitt og prevensjonsmidler.]
  235. Addendum. Manual IX: the methodology of measuring the impact of family planning programmes on fertility.
  236. Addendum: Manual IX. The methodology of measuring the impact of family planning programmes on fertility.
  237. Administrative innovations in the family planning program: acase study. [Innovaciones administrativas del programa de planificacion familiar: estudio de caso.]
  238. Adolescence and choice of contraceptive. [Adolescence et choix contraceptif.]
  239. The adolescent and contraception. Part 2. [L'adolescent et la contraception. 2 partie.]
  240. The adolescent and contraception: psychological factors. [L'adolescente et la contraception: aspects psychologiques.]
  241. Adolescent contraception.
  242. The adolescent dilemma: international perspectives on the family planning rights of minors.
  243. The adolescent facing contraception: methods. [La adolescencia frente a la anticoncepcion: metodos.]
  244. Adolescent male involvement and contraception: a fifteen year review of the literature (1970 - 1985)
  245. Adolescent sexuality and family planning awareness, knowledge, attitude and behavior: Taiwan.
  246. Adolescent sexuality, contraceptive health and STD.
  247. Adolescents and contraception. Part 1. [L'adolescent et la contraception. 1re partie.]
  248. Adolescents: planning contraceptive and counselling services.
  249. Advantages and disadvantages of each contraceptive method. [Motifs de satisfaction et d'insatisfaction dans l'utilisation des methodes contraceptives.]
  250. Adverse metabolic effects of oral contraceptives.
  251. Advice for girls under 16 on contraception and pregnancy.
  252. Affective and physical changes associated with oral contraceptive use.
  253. An age and parity dependent model for birth intervals of non-contraceptive population.
  254. Agricultural development and adoption of family planning.
  255. Alcohol consumption, female sexual behavior and contraceptive use.
  256. Allowable duration for using intrauterine polyethylene contraceptives. [Dopustimaia dlitelnost primeneniia polietilenovykh vnutrimatochnykh kontratseptivov.]
  257. Alternatives to expand family planning services in Brazil. [Operations research project summary]
  258. American teens speak: sex, myths, TV, and birth control. The Planned Parenthood Poll.
  259. Analysis of the association between previous contraceptive use and the incidence of cervico-uterine cancer in women from the northern and eastern area of Santiago. [Analisis de la asociacion entre uso previo de anticonceptivos e incidencia de cancer cervicouterino en mujeres del area norte y oriente de Santiago.]
  260. Angiographic findings after myocardial infarction in women aged less than or equal to 50 years -- role of oral contraceptives.
  261. An annotated bibliography of the Nigerian fertility and family planning literature up to 1982.
  262. Antacid does not reduce the bioavailability of oral contraceptive steroids in women.
  263. Antibodies to cardiolipin and vascular complications in women taking oral contraceptives [letter]
  264. Appendicitis caused by an intrauterine contraceptive device.
  265. Applicable experiences. Review of the Integrated Project, 1975 - 1985 and its future direction. The 7th Workshop on the Management of the Integrated Family Planning Nutrition and Parasite Control, December 4-11, 1985, Tokyo, proceedings.
  266. Are research projects necessary for a successful family planning program? Cheju Project.
  267. Area differences in fertility and contraception among Indian,Coloured, and black South Africans. [Streeksverskille in fertiliteit en kontrasepsie onder Indier-, Kleurling- en Swart Suid-Afrikaners.]
  268. Aspects of family planning among Blacks in Western Transvaal: regarding their knowledge of it, attitudes, communication and exposure to mass media. [Gesinsbeplanning onder Swartes in Wes-Transvaal: enkele aspekte van hulle kennis, houdings, kommunikasie en massamediagebruik.]
  269. Assessing costs and benefits of incorporating family planning service delivery into pre-paid health maintenance organization plan in Brazil.
  270. Assessing your organizational assets. A manual for managers of private voluntary organizations involved in family planning. Draft.
  271. An assessment of psychological state associated with the menstrual cycle in users of oral contraception.
  272. Attempt to elaborate an explanating model of adolescents' contraceptive behavior. [Essai d'elaboration d'un modele explicatif du comportement contraceptif des adolescentes.]
  273. Attitudes of women and men toward contraception in a town in Burkina Faso.
  274. Attitudes of women and men towards contraception in Bobo-Dioulasso.
  275. Availability and accessibility of contraception: a worldwide public health problem.
  276. Availability of contraceptive methods. [Disponibilidad de metodos anticonceptivos.]
  277. Bangladesh Contraceptive Prevalence Survey - 1983, special topics.
  278. Bangladesh Contraceptive Prevalence Survey - 1983: household questionnaire.
  279. Bangladesh Contraceptive Survey--1983, special topics.
  280. Barriers to modern contraceptive use in rural Peru.
  281. Barriers to the use of contraception in 4 U.S. cities: results from focus groups.
  282. Baseline studies and evaluation of health benefits attributable to an integrated family planning and maternal/infant care service, [Soonchunhyang University, College of Medicine]. Operations research project summary.
  283. Baseline study on the Integrated Project on Family Planning, Parasite Control and Nutrition in Zambia.
  284. The basic pharmacology, pharmacokinetics and drug interactions of hormonal contraceptives.
  285. Basic survey on population and family planning in the People's Republic of China.
  286. Basilar artery occlusion in an adolescent girl: risk of oral contraceptives?
  287. Be wary of methodology and biases in reading contraceptive failure rates.
  288. The bedroom and the state: the changing practices and politics of contraception and abortion in Canada, 1880-1980.
  289. Beneficial and adverse side-effects of hormonal contraception.
  290. Benefits and risks of contraception.
  291. Benign hepatic tumors and oral contraceptives: the management of intra-hepatic hematoma is not always an operative emergency. [Faut-il operer (en urgence) les hematomes sous-capsulaires du foie sur tumeur benigne?]
  292. Benign liver tumors and oral contraceptives; diagnosis and treatment (letter) [Benigne levertumoren en orale anticonceptiva; diagnostiek en behandeling.]
  293. Beyond family planning: incentives in Taiwan.
  294. Bilateral ballism induced by oral contraceptives: a case report.
  295. Biological activity of oral contraceptives.
  296. A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer.
  297. Birth control and family planning. Round table. [Controle da natalidade x planejamento familiar. Mesa-Redonda.]
  298. Birth control by assetless workers in Kerala: the possibility of a poverty induced fertility transition.
  299. Birth control failure among patients with unwanted pregnancies: 1982-1984.
  300. Birth control failure.
  301. Birth control method and device employing electric forces.
  302. Birth control method should suit your lifestyle.
  303. Birth control: vanishing options.
  304. The birth-control book.
  305. Brazil: federal government incorporates family planning in the Social Security System.
  306. Breast cancer and the use of oral contraceptives [letter]
  307. Breast cancer risk in relation to early oral contraceptive use.
  308. Bringing family planning to the people. A Conference on Community-Based Distribution and Alternative Delivery Systems in Africa, [Harare, Zimbabwe, 3-7 November 1986]
  309. Can family planning reduce maternal mortality?
  310. Cancer of the liver and the use of oral contraceptives.
  311. Cancer risks and the contraceptive pill. What is the evidence after nearly 25 years of use?
  312. Candidosis and oral contraception [letter]
  313. Capacitation and fertilization: acrosin inhibitors (aryl 4-guanidinobenzoates) as vaginal contraceptives.
  314. Carbohydrate tolerance and serum lipid responses to type of dietary carbohydrate and oral contraceptive use in young women.
  315. Cardiovascular risk status and oral contraceptive use: United States, 1976-1980.
  316. Care of women taking oral contraceptive drugs (letter) [Az oralis antikoncipienst szedok gondozasarol.]
  317. Carrying out the number seven directive of C.C.C.C.P., spreading comprehensive measures of birth control.
  318. Cerebral venous thrombosis associated with the use of oral contraceptives.
  319. Cerebrovascular complications of oral contraceptives. Review of the literature; report of 2 cases. [Complications cerebro-vasculaires des contraceptifs oraux. Revue de la litterature (a propos de 2 observations)]
  320. Cervical cancer and hormonal contraceptive use in Costa Rica [abstract]
  321. The cervical cap as a barrier contraceptive.
  322. The cervical cap: effectiveness, safety, and acceptability as a barrier contraceptive.
  323. Cervical mucus and contraception.

     

  324. Changes in health and family planning practice and demographic trends, Mojokerto, East Java, 1974 - 1978.
  325. Characteristics of new contraceptive acceptors in Zimbabwe.
  326. Characteristics of users of traditional contraceptive methods in Bangladesh.
  327. Characterization of the fertilization antigen 1 for the development of a contraceptive vaccine (high performance liquid chromatography / two-dimensional gel electrophoresis)
  328. Chemical seller's contraceptive training manual. Ghana Social Marketing Programme contraceptive and family planning training manual.
  329. Children, medical treatment and contraceptive agents: is parental consent necessary?
  330. A church divided. Catholics' attitudes about family planning, abortion and teenage sexuality.
  331. Ciudad Juarez Family Planning Program, Mexico-24 Modification no. 7, project description and budget.
  332. Clinical and endocrine effects of long-term hormonal contraception.
  333. The collaboration between the Family Planning Association of Guyana and the government. [De samenwerking tussen de family planning organisatie van Guyana en de overheid.]
  334. The collection of information on contraceptive practice: results of a survey by INED-INSEE in 1978. [La colledte des donnees sur les pratigues contraceptives: les enseignements de l'enquete INED-INSEE de 1978.]
  335. Combining vertical service with horizontal service to promote family planning.
  336. Comment: drug interactions with oral contraceptives [letter]
  337. Commentary: oral contraceptives and atherogenesis.
  338. Communication messages and effectiveness of family planning education.
  339. Community based primary health and family planning in church sponsored programs in Kenya: analysis of baseline family planning data.
  340. The community participation approach in family planning programmes: some suggestions for project development.
  341. Community-based incentives: increasing contraceptive prevalence and economic opportunity.
  342. The comparative approach to myco-bacterial vaginal investigations of female students who take local and oral contraceptives.
  343. Comparing contraceptives.
  344. Comprehensive understanding of "truth of China's family planning practices".
  345. Conception and contraception in diabetics. [Conception et contraception chez les diabetiques.]
  346. Concerning the decline in fertility and contraception in Sao Paulo (a preliminary analysis) [Sobre o declinio da fecundidade e a anticoncepcao em Sao Paulo (analise preliminar)]
  347. Condom distribution through family planning clinic patients, Emory/Grady Family Planning Program.
  348. Congenital limb reduction deformities and use of oral contraceptives.
  349. Consultation report, Ghana. Assessment of the possibility of providing family planning services within the framework of employee health benefits, 21 May - 3 June 1986.
  350. Consumer warnings for oral contraceptives: a new exception to the prescription drug rule.
  351. Contraception -- then, now and tomorrow.
  352. Contraception a year after induced abortion. [Contraception un an apres une interruption volontaire de grossesse.]
  353. Contraception acceptability among a group of newly delivered mothers in Jordan.
  354. Contraception after pregnancy termination.
  355. Contraception among female students in the University of Benin.
  356. Contraception and chronic illnesses: a clinician's sourcebook.
  357. Contraception and computer sciences: SELF, a system of assistance in medical decisions, applied to the prescription of contraceptive methods. [Contraception et informatique: SELF, un systeme d'aide a la decision medicale applique a la prescription des methodes contraceptives.]
  358. Contraception and diabetes mellitus.
  359. Contraception and pelvic infection in women. [Contraception et infection pelvienne chez la femme.]
  360. Contraception and procreation: phenomena in the arrival of a child. [Empfangnis und Zeugung: Phanomene der Kindesankunft.]
  361. Contraception and the Catholic doctor: the question of referrals.
  362. Contraception and the cervix.
  363. Contraception and the law: medical-legal trends affecting availability of contraception in the United States.
  364. Contraception and the problems of its use. [Kontracepcija i problemi njene primene.]
  365. Contraception by long-acting steroids. [Hormonale Kontrazeption mit Depotpraparaten.]
  366. Contraception for the adolescent [letter]
  367. Contraception for women forty and over.
  368. Contraception gone awry. Women were promised safe, effective birth control: What happened?
  369. Contraception in adolescent girls: the point of view of the gynecologist. [Contraception des adolescentes; point de vue du gynecologue.]
  370. Contraception in pre-menopause. [Kontrazeption in der Pramenopause.]
  371. Contraception in Spain: a study of current use, knowledge and perceptions of contraceptive methods.
  372. Contraception in the Federal Republic of Germany, a study of current use, knowledge and perceptions of contraceptive methods.
  373. Contraception in the female transplant recipient.
  374. Contraception in the USA--an unfavourable climate.
  375. Contraception in women with diabetes mellitus. [Anticonceptie bij vrouwen met diabetes mellitus.]
  376. Contraception use and annual acceptors required for fertility transition: results of a projection model.
  377. Contraception with pure, synthetic progestogens of the norpregnane group, a new approach for the future? [La contraception par progestatifs de synthese purs du groupe norpregnane, nouvelle voie d'avenir?]
  378. Contraception, pregnancy, childbirth--when things go wrong.
  379. Contraception--the next 25 years.
  380. Contraception--with us and others. [Antikonception--hos oss och andra.]
  381. Contraception.
  382. Contraception.
  383. Contraception: the French were the first, but why? [Contraception: les Francais les premiers, mais pourquoi?]
  384. Contraception: are implants the answer?
  385. Contraception: methods and counselling.
  386. Contraceptive advice: how the English differ from the Americans.
  387. Contraceptive agents and antithrombin III. New causes of thrombosis (letter) [P-piller og antitrombin III. "Nye" araker til trombose.]
  388. Contraceptive availability.
  389. Contraceptive behavior of spouses in urban families. [Kontratseptivnoe povedenie suprugov v gorodskikh sem'yakh.]
  390. Contraceptive care and family planning in an urban general practice.
  391. Contraceptive care and family planning: a correction [letter]
  392. Contraceptive choices for sexually active young women.
  393. Contraceptive choices in Bangladesh.
  394. Contraceptive development and clinical trials.
  395. Contraceptive development--the view from the U.S.A. in the mid 80s. [Developpement de produits contraceptifs: la situation aux U.S.A. au milieu des annees 1980.]
  396. The contraceptive diaphragm: is it an acceptable method in the 1980s?
  397. Contraceptive distribution in factories in St. Lucia. Final report.
  398. Contraceptive failure in the United States: estimates from the 1982 National Survey of Family Growth.
  399. Contraceptive hormones and their clinical use.
  400. Contraceptive initiation and the demand for children.
  401. Contraceptive knowledge and attitudes in urban Ilorin, Nigeria.
  402. Contraceptive knowledge, attitudes, and practice.
  403. Contraceptive method choice in Thailand: an analysis from the 1985 Survey of Fertility in Thailand.
  404. Contraceptive methods used by female diabetic patients. [Les methodes contraceptives actuelles utilisees par nos patientes diabetiques.]
  405. Contraceptive needs of breast-feeding women.
  406. Contraceptive needs of the developing world.
  407. Contraceptive perceptions and method choice among young single women in the United States.
  408. Contraceptive potential of antisperm antibodies.
  409. Contraceptive practice among Hispanic adolescents.
  410. Contraceptive practice and fertility in Thailand: results of the third Contraceptive Prevalence Survey.
  411. Contraceptive practice and social class in Mexico: recent experience. [Practica anticonceptiva y clases sociales en Mexico: la experiencia reciente.]
  412. Contraceptive practice: selected findings from the World Fertility Survey data.
  413. Contraceptive practices among female heroin addicts.
  414. Contraceptive practices of female physicians.
  415. Contraceptive prevalence in the slums of Rio de Janeiro.
  416. Contraceptive self-efficacy: a perspective on teenage girls' contraceptive behavior.
  417. Contraceptive social marketing [memorandum]
  418. Contraceptive social marketing report [memorandum]
  419. Contraceptive social marketing.
  420. Contraceptive sterilization in Puerto Rico.
  421. Contraceptive steroid concentrations in women with early active schistosomiasis: lack of effect of antischistosomal drugs.
  422. Contraceptive steroid effects on nonreproductive organ systems.
  423. Contraceptive steroid effects on serum lipoproteins and lipoprotein subclasses.
  424. Contraceptive steroids and thrombosis.
  425. Contraceptive steroids increase hepatic uptake of chylomicron remnants in healthy young women.
  426. Contraceptive technology 1986-1987 (13th rev. ed.)
  427. Contraceptive technology 1986-1987, 13th revised edition.
  428. The contraceptive transition in Flanders.
  429. Contraceptive use among young women.
  430. Contraceptive use and breastfeeding: their inverse relationship and policy concern.
  431. Contraceptive use and childbearing in contemporary Japan.
  432. Contraceptive use and effectiveness.
  433. Contraceptive use and experience amongst a sample of women attending their GP.
  434. Contraceptive use and pregnancy outcome in Chiang Mai, Northern Thailand.
  435. Contraceptive use in the chronically ill adolescent female. part II.
  436. Contraceptive use in the chronically ill adolescent female: part I.
  437. Contraceptive use, a comparison between ever-and never-pregnant adolescents.
  438. Contraceptive use.
  439. Contraceptive use: United States, 1982.
  440. Contraceptive vasectomy: does it have a future in France? [La vasectomie contraceptive: a-t-elle un avenir en France?]
  441. A contraceptives handbook.
  442. A cost effectiveness analysis of the family planning programs in Nepal.
  443. A cost-benefit analysis of the Mexican social security administration's family planning program.
  444. Cost-effectiveness of family planning in India: the long-run average and marginal costs.
  445. Council of Europe Committee of Ministers resolution (75) 29 on legislation relating to fertility and family planning.
  446. Council of Europe resolutions on family planning.
  447. Counselling in family planning.
  448. Counter reformation in family planning.
  449. Couple communication and sexual attitudes in natural family planning.
  450. The criminal law aspects of planned parenthood. [De strafrechtelijke aspecten van gezinsplanning.]
  451. Cross-cultural comparison of contraceptive knowledge, attitudes, and behavior of selected black American and Nigerian university students.
  452. Cultural, moral and religious aspects of family planning. [Aspects culturels, moraux et religieux du planning familial.]
  453. CUP: contraceptive users pamphlet.
  454. The current population status and family planning of national minorities.
  455. Current status and recommendations concerning breastfeeding and the use of contraceptives in Honduras: Sept. 1984.
  456. Current status of family planning in Japan.
  457. Current usage of and attitudes towards contraception in Australia.
  458. Cutaneous melanoma and oral contraceptives: a review of case-control and cohort studies.
  459. Cytological study of the mode of contraceptive action of nonoxynol-9. [Etude cytologique du mode d'action contraceptive du nonoxynol-9.]
  460. Daily and monthly work routines of the government family planning worker: the family welfare assistant (FWA)
  461. Danazol: a new hormonal post-coital contraceptive method. [Danazol: nouvelle methode de contraception hormonale post-coitale.]
  462. A decade of intrauterine contraception: 1976 to 1986.
  463. Defending planned parenthood rights: the role of the PPA, IPPF, and the state.
  464. Definitive birth control and the physician--ethical issues.
  465. Delivery of family planning and health services in campesino and indigenous communities in Ecuador. [Operations research project summary]
  466. Delivery of family planning on the basis of reproductive risk.
  467. Demographic and health surveys. Model questionnaires with commentary for high contraceptive prevalence countries.
  468. Demographic and health surveys: model questionnaires with commentary for low contraceptive prevalence countries.
  469. Demographic behavior and family planning in Romania. [Demografskoto povedenie i planiraneto na semeistvoto v Rumaniya.]
  470. Dermatologic complications of oral hormonal contraception (Gravistat) [Dermatologiczne powiklania doustnej antykoncepcji hormonalnej (Gravistat)]
  471. Descriptive study on sexual patterns of contraceptive and sexual attitudes and behavior in rural areas and urban Michoacan, Mexico. [Estudio descriptivo de las normas y conductas sexuales y anticonceptivas en los medios rural y urbano de Michoaca, Mexico.]
  472. Design and conduct of clinical trials of contraceptive methods [letter]
  473. Design and findings of Egypt Contraceptive Prevalence Survey, 1984.
  474. Early oral contraceptive use and breast cancer risk [letter]
  475. Early oral contraceptive use and breast cancer: theoretical effects of latency.
  476. The economics of contraceptive social marketing.
  477. Ectopic pregnancy with a coexistent intrauterine contraceptive device. [Ciaza ektopowa przy wspolistnieniu wewnatrzmacicznej wkladki antykoncepcyjnej.]
  478. Education in family planning in Indonesia.
  479. Education, fertility and family planning practices in a rural area of Bangladesh.
  480. The effect of an oral contraceptive containing ethinylestradiol and desogestrel on hair growth and hormonal parameters of hirsute women.
  481. Effect of development of rural commodity economy on family planning.
  482. Effect of education and employment on the value-systems and marital-role preferences of boys and girls in early twenties with regard to family planning. Summary.
  483. Effect of hormonal contraception on the level of some serum proteins. [Vliv hormonalni antikoncepce na hladinu nekterych serovych bilkovin.]
  484. The effect of induced abortion on subsequent contraceptive practices.
  485. Effect of oral and injectable contraceptives on low density and high density lipoproteins.
  486. The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women.
  487. Effect of oral contraceptives and pregnancy on iron metabolism, plasma lactoferrin and granulocyte count in women. [Der Einfluss hormoneller Kontrazeptiva und der Schwangerschaft auf Eisenstoffwechsel, Plasmalactoferrinkonzentration und Granulozytenzahl der Frau.]
  488. Effect of oral contraceptives on leukocyte phagocytic activity and plasma levels of prostaglandin E2 and tromboxane B2 in normal menstruating women.
  489. Effect of oral contraceptives on serum prolactin: a longitudinal study in 126 normal premenopausal women.
  490. The effect of oral contraceptives on the apparent vitamin-B6 status in some Sudanese women.
  491. The effect of sex preference on fertility and family planning: empirical evidence.
  492. The effect of sodium lauryl sulphate on the viscosity of vehicles for vaginal contraceptives with sodium carboxymethylcellulose and Veegum HV.
  493. Effect of subdermal levonorgestrel contraceptive implants on vaginal candidiasis.
  494. The effects of formal sex education on adolescent intercourse, contraception and pregnancy in the United States.
  495. The effects of oral contraceptive use on lipoproteins: significance for atherosclerosis.
  496. Effects of oral contraceptives and tobacco use on the metabolic pathways of theophylline.
  497. Effects of oral contraceptives on carbohydrate metabolism.
  498. Effects of oral contraceptives on cholesterol.
  499. Effects of oral contraceptives on fibrinolytic system among Japanese and American women.
  500. Effects of oral contraceptives on lipid metabolism.

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.